» Articles » PMID: 15286962

Value of Positron Emission Tomography in the Diagnosis of Recurrent Oesophageal Carcinoma

Overview
Journal Br J Surg
Specialty General Surgery
Date 2004 Aug 3
PMID 15286962
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Positron emission tomography (PET) with [18F]fluorodeoxyglucose (FDG) might be useful for staging oesophageal squamous cell carcinoma (SCC). FDG-PET may be more accurate than computed tomography (CT) in diagnosing lymph node metastasis. This retrospective study compared the ability of FDG-PET and CT to diagnose recurrent oesophageal carcinoma.

Methods: Fifty-five patients with thoracic oesophageal SCC who had undergone radical oesophagectomy were studied. The accuracy of FDG-PET and CT in detecting recurrence during follow-up was calculated using data from the first images generated by either modality that suggested the presence of recurrent disease. Lesions deemed to be equivocal on these scans were considered as positive for recurrence.

Results: Twenty-seven of the 55 patients had recurrent disease in a total of 37 organs. Locoregional recurrence was observed in 19 patients (35 per cent). Distant recurrent disease occurred in 15 patients (27 per cent) in 18 organs. Six patients had recurrence in the liver, four in the lung, six in bone and two in distant lymph nodes. FDG-PET showed 96 per cent sensitivity, 68 per cent specificity and 82 per cent accuracy in demonstrating recurrent disease. The corresponding values for CT were 89, 79 and 84 per cent. The sensitivity of FDG-PET was higher than that of CT in detecting locoregional recurrence, but its specificity was lower because of FDG uptake in the gastric tube and thoracic lymph nodes. In distant organs the sensitivity of PET in detecting lung metastasis was lower than that of CT, but its sensitivity for bone metastasis was higher.

Conclusion: FDG-PET has a larger field than CT. Combined PET-CT would appear to be an appropriate modality for the detection of recurrent oesophageal cancer.

Citing Articles

The application of radiomics in esophageal cancer: Predicting the response after neoadjuvant therapy.

Guo H, Tang H, Hu W, Wang J, Liu P, Yang J Front Oncol. 2023; 13:1082960.

PMID: 37091180 PMC: 10117779. DOI: 10.3389/fonc.2023.1082960.


F-FDG PET/CT Parameters for Predicting Prognosis in Esophageal Cancer Patients Treated With Concurrent Chemoradiotherapy.

Lee S, Choi Y, Park G, Jo S, Lee S, Park J Technol Cancer Res Treat. 2021; 20:15330338211024655.

PMID: 34227434 PMC: 8264725. DOI: 10.1177/15330338211024655.


Role of precision imaging in esophageal cancer.

Elsherif S, Andreou S, Virarkar M, Soule E, Gopireddy D, Bhosale P J Thorac Dis. 2020; 12(9):5159-5176.

PMID: 33145093 PMC: 7578477. DOI: 10.21037/jtd.2019.08.15.


FDG-PET/CT is useful in the follow-up of surgically treated patients with oesophageal adenocarcinoma.

Betancourt Cuellar S, Palacio D, Wu C, Carter B, Correa A, Hofstetter W Br J Radiol. 2017; 91(1082):20170341.

PMID: 29125331 PMC: 5965786. DOI: 10.1259/bjr.20170341.


Patterns and rates of abdominal lymphatic metastasis following esophageal carcinoma.

Chen J, Cai W, Lin Y, Chen Y, Zheng Q, Pan J PLoS One. 2017; 12(10):e0185424.

PMID: 29016614 PMC: 5634562. DOI: 10.1371/journal.pone.0185424.